Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 3, 2008, Pages 301-309

  Aarts, Frits ^a   Hendriks, Thijs ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Bleichrodt, Robert P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytoreductive surgery; Fibrinolytic therapy; Hyperthermia; Peritoneal carcinomatosis; Radioimmunotherapy; Targeted radionuclide therapy

Indexed keywords

ALTEPLASE; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MG1 LUTETIUM LU 177;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FIBRINOLYTIC THERAPY; HYPERTHERMIC THERAPY; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RAT; TREATMENT OUTCOME;

ANIMALS; BODY WEIGHT; CARCINOMA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HYPERTHERMIA, INDUCED; MALE; NEOPLASM TRANSPLANTATION; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RATS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 46449117860     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0455     Document Type: Article

References (37)

1. Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006;243:212.
2. van Ruth S, Verwaal VJ, Hart AA, et al. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res 2003;23:1501.
3. Sugarbaker PH. Colorectal carcinomatosis: a new oncologic frontier. Curr Opin Oncol 2005;17:397.
4. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284.
5. Verwaal VJ, van RS, de BE, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737.
6. Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747.
7. Culliford AT, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001;8:787.
8. Elias D, Blot F, El OA, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71.
9. Koppe MJ, Bleichrodt RP, Oyen WJ, et al. Radioimmunotherapy and colorectal cancer. Br J Surg 2005;92:264.
10. Koppe MJ, Hendriks T, Boerman OC, et al. Radioimmunotherapy is an effective adjuvant treatment modality after cytoreductive surgery of peritoneal carcinomatosis of colonic origin. J Nucl Med 2006;47:1867.
11. Aarts F, Koppe MJ, Hendriks T, et al. Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2007;14:533.
12. Aarts F, Hendriks T, Boerman OC, et al. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol 2007;14:3274.
13. Kinuya S, Yokoyama K, Hiramatsu T, et al. Optimal timing of administration of hyperthermia in combined radioimmunotherapy. Cancer Biother Radiopharm 2000;15:373.
14. Horsman MR. Tissue physiology and the response to heat. Int J Hyperthermia 2006;22:197.
15. Gerner EW, Connor WG, Boone ML, et al. The potential of localized heating as a adjunct to radiation therapy. Radiology 1975;116:433.
16. Schlemmer M, Lindner LH, bdel-Rahman S, et al. [Principles, technology and indication of hyperthermia and part body hyperthermia]. Radiologe 2004;44:301.
17. Holmdahl L, Eriksson E, Eriksson BI, et al. Depression of peritoneal fibrinolysis during operation is a local response to trauma. Surgery 1998;123:539.
18. Scott-Coombes D, Whawell S, Vipond MN, et al. Human intraperitoneal fibrinolytic response to elective surgery. Br J Surg 1995;82:414.
19. Neudecker J, Junghans T, Raue W, et al. Fibrinolytic capacity in peritoneal fluid after laparoscopic and conventional colorectal resection: data from a randomized controlled trial. Langenbecks Arch Surg 2005;390:523.
20. Nagy JA, Meyers MS, Masse EM, et al. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995;55:369.
21. Biggerstaff JP, Seth N, Amirkhosravi A, et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 1999;17:723.
22. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747.
23. Zedeck MS. A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate. J Natl Cancer Inst 1974;53:1419.
24. Hagenaars M, Koelemij R, Ensink NG, et al. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metastasis 2000;18:281.
25. Koppe MJ, Bleichrodt RP, Soede AC, et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45:1224.
26. Kinuya S, Yokoyama K, Hiramatsu T, et al. Optimal timing of administration of hyperthermia in combined radioimmunotherapy. Cancer Biother Radiopharm 2000;15:373.
27. Buyne OR, Bleichrodt RP, van GH, et al. Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model. Int J Colorectal Dis 2007;22:819.
28. Lopes Cardozo AM, Gupta A, Koppe MJ, et al. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 2001;27:359.
29. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487.
30. Saga T, Sakahara H, Nakamoto Y, et al. Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur J Cancer 2001;37:1429.
31. Song CW, Park HJ, Lee CK, et al. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005;21:761.
32. Kinuya S, Yokoyama K, Hiramatsu T, et al. Optimal timing of administration of hyperthermia in combined radioimmunotherapy. Cancer Biother Radiopharm 2000;15:373.
33. Mittal BB, Zimmer AM, Sathiaseelan V, et al. Effects of hyperthermia and iodine-131-labeled anticarcinoembryonic antigen monoclonal antibody on human tumor xenografts in nude mice. Cancer 1992;70:2785.
34. Reijnen MM, Bleichrodt RP, Van Goor H. Pathophysiology of intra-abdominal adhesion and abscess formation, and the effect of hyaluronan. Br J Surg 2003;90:533.
35. Oosterling SJ, van der Bij GJ, van EM, et al. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur J Surg Oncol 2005;31:29.
36. Jacquet P, Stuart OA, Dalton R, et al. Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites. J Surg Oncol 1996;62:128.
37. Zalutsky MR, Reardon DA, Pozzi OR, et al. Targeted alpha-particle radiotherapy with (211)At-labeled monoclonal antibodies. Nucl Med Biol 2007;34:779.